triamcinolone + lidocaine (University of California, San Francisco)

This combination therapy is utilized as the standard care (SOC) treatment component in a Phase 4 randomized controlled trial (NCT07278323) conducted by the University of California, San Francisco (UCSF) for adhesive capsulitis of the shoulder (frozen shoulder). The treatment protocol involves ultrasound-guided glenohumeral joint injections. The corticosteroid component, specifically triamcinolone acetonide, serves as a potent anti-inflammatory agent that targets inflammatory pathways by acting as a glucocorticoid receptor agonist. Lidocaine and ropivacaine are local anesthetics that provide immediate and short-term pain relief by blocking voltage-gated sodium channels. In the context of the UCSF study, this combination is used alongside physical therapy to establish a baseline for evaluating the efficacy of Hormone Replacement Therapy (HRT) as an adjunct treatment in peri- and postmenopausal women.

Other names

Corticosteroid and 1%lidocaintriamcinolone + lidocaine + ropivacaine